Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hopefully there can be a positive update on the India income soon, confirming the forecast of £14 -15 million per year coming in month by month from now on, including this January? Such confirmation should send the SP securely upward.
The earth keeps turning , the days keep passing and the May deadline for the Cameroon site gets critically closer.
If finance is not sorted well before end of February, getting the drill done before the May expiry will be looking impossible? So, Tower is really entering the last chance saloon for this and any remaining credibility of JA.
I hope it comes through to prove I'm not stupidly over-invested here.
Mr Ripley I have merely made a valid point about how this company's statements may be seen by the wider market of traders outside this somewhat biased chat board.
I'm hopeful of big things from the company but frustrated with them.
Your big AL DOES still has some questions to answer about the Covid Test fiasco.
~The presentation style is slow / wooden at the start but, overall it's a very positive informative presentation. This company really would seem to be on the cusp of a major step change to serious profitability.
Any access to the presentation now?
There have been so many positive research results about Angle's Parsortix and they got the long awaited FDA approval that may of us thought would be the trigger for solid SP rise.
What will it take to get this SP moving genuinely, robustly upward?
MCB - the RNS about the poster says the poster slot is 1.30 pm to 5.30 pm on April 11th and AVACTA will be represented by Fiona McLaughlin, PhD, Chief Scientific Officer and Neil Bell, Chief Development Officer (part of RNS copied below):-
So I think you may have wires crossed if you think there is to be some sort of set-piece "presentation" of 9 mins or so at 18:15 pm to some overall audience totally focused on Avacta's "poster".
I think "poster presentation" conferences take the form of conference halls with walk round routes of multiple presenter 'stands' for delegates to walk around look at poster presented on the stands . "Presenters" stand by their poster and talk to delegates who show interest in conversation when looking at the poster? ~Isn't that what this event is?
Poster presentation Title: AVA6000, a novel Precision medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage.
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Targets
Session Date and Time: Monday Apr 11, 2022 1:30 PM - 5:00 PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H
Abstract Number: #1815
Presenter: Fiona McLaughlin, PhD, Chief Scientific Officer and Neil Bell, Chief Development Officer, Avacta Life Sciences Ltd.
Greedo -
To me, 2.5 months seems more than enough time to find a replacement antibody, if AVACTA was half-serious about re-instating an LFT and recovering some reputation. However, sadly, when it comes to such, the track record is that Avacta is appallingly slow and not particularly aware of how to progress commercially in real time.
Still, we all live in hope that things will change and performance will turn for the better.
ProfCheese - I think you're right, AVACTA now has a huge credibility issue to overcome. The LFT stands as a company shambles. They urgently need to prove they can reset it to deal with Omicron and show how they will be able to quickly (QUICKLY) adapt to other variants.
Valueinv - perhaps they're not buying because they're not confident to buy -given they know what a total balls up they made of the golden opportunity that was the LFT. That balls up doesn't mode well for the Cancer opportunity.
Ash78 - I think you've hit a nail on the head :- Smith is hopeless - seemingly no proactive research preparation or anticipation of requirements or scenario developments. On top of which, he makes misleading optimistic statements which then unravel; he's created the current market loss of confidence - as evidenced by the appalling fall in the shareprice - pretty much single-handedly in respect of his communications ; not least the recent careless comment about the LFT replacement now taking 'some time' after previously suggesting it wouldn't take long. Now , no other way to regard this other than CEO sh_t -show.
But I've already let it my holding slip to having too much loss to sell now, so am stuck with hoping for some sort of recovery via build of positivity around the cancer treatment (which is what I was originally in for).
But the LFT farce does not bode well for Cancer treatment progress and any successful follow through.